Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges

By Patrick Wingrove Oct 29 (Reuters) – Eli Lilly raised its full-year revenue forecast and beat third-quarter earnings expectations on Thursday, propelled by surging demand for injectable weight-loss drugs that could allay investor concerns about price erosion in US government health plans. The Indianapolis-based drugmaker now expects full-year revenue of $91 billion to $92 billion, underscoring…

Daisy May Cooper displays incredible 10st weight-loss in a vampy mini-dress and thigh-high boots as she leaves viewers in hysterics on the Last One Laughing… — Daily Mail · Right
Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges — Salem Radio Network News · Right
Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges — Regional Media News · Right
Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges — WNCY - 100.3 FM - Green Bay

Open True Mainstream to compare left, right, and center coverage